🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Do not miss the Y-ECI session at the HNCG meeting this Saturday 27.04.2024 at 11 am CET. See the agenda below 🤓👩‍⚕️👨‍⚕️

📣 Our review and metanalysis on IO in elderly HNSCC pts is now out! First paper coming from the EORTC HNCG YI group 🤓☺️ led by ⁦Viola Salvestrini⁩ and Petr Szturz. Check it out 👇🏻 frontiersin.org/journals/oncol…

📢Eager to see some of the most interesting abstracts on new therapies at this ASCO meeting in HNSCC field!Preliminary info 🔬Here my personal selection👇 ASCO OncoAlert TTCC-GrupoTratamiento Tumores Cabeza y Cuello

Important and completely counter intuitive study ! The NGR-LU002 stydy shows that the irradiation of all sites (primary+mets) after induction chemo or chemo-IO does not increase survival compared to the standard maintenance treatment. « Le mieux est l’ennemi du bien » #ASCO24

Radiation Therapy for HPV-Positive Oropharyngeal Squamous Cell Carcinoma: An ASTRO Clinical Practice Guideline - Practical Radiation Oncology practicalradonc.org/article/S1879-…

🔈🔈interim analysis of Trilynx ph3 study: crossed the futility boundary 😵‍💫 emdgroup.com/en/news/xevina…

June 2024 newsletter out now (contains links to full versions of the Lancet Onc series!) headneckcig.org/_files/ugd/31d…

Join us tomorrow and Friday for the ESMO - Eur. Oncology Virtual Plenary on HNSCC👇🏻 Full program and how to access: esmo.org/meeting-calend…

Bacteria in metastatic sites: Unveiling hidden players in cancer progression dlvr.it/T9Vrt5

Deciphering the impact of STAT3 activation mediated by PTPRT promoter hypermethylation as biomarker in squamous cell carcinoma of the head and neck Institut Català d'Oncologia IGTP TTCC-GrupoTratamiento Tumores Cabeza y Cuello FETTCC Fundación E. Tto. Tumores Cabeza y Cuello

Current Landscape of Antibody-Drug Conjugate Development in Head and Neck Cancer | JCO Precision Oncology ascopubs.org/doi/full/10.12…

EORTC-1206: Double androgen blockade (bicalutamide + leuproreline) vs chemotherapy in AR+#salivaryglandcancer: ⛔️no benefit for frontline CAB, low response rates. Better to use combined or sequential approach? and what in HER2+ AR+ SGC? @EORTC_HNCG_YI ESMO - Eur. Oncology #ESMO2024

Did you know that around 700 000 people worldwide get #headandneckcancer, about 100 000 are attributed to #HPV infection. Prevention is the 🗝️to reduce cancer burden: stop tobacco 🚭& alcohol abuse, and increase vaccination rate 💉 Make Sense Campaign @EORTC_HNCG_YI

Hi all: The full newsletter can be found on this link: eortchq.sharepoint.com/:b:/s/Filebox/…

Stay tuned for Y-ECI session on Oct 12th 12 to 13.00 CET: agenda below 🤓👇🏻. Info on Registration can be found the cited tweet 😊

Congrats to Maryann Zhao on leading this NatureRevClinOncol review of #scRNASeq studies on #Tcell dynamics in #neoadjuvant ICI treated #HNSCC patients! Glenn J. Hanna, M.D. Robert Haddad Jonathan Schoenfeld R. Bryan Bell, MD, DDS, FACS, FRCS(Ed) rdcu.be/d22hn

📣 New ESMO–EURACAN #ClinicalPracticeGuideline in #SinonasalMalignancy includes treatment advances in #radiotherapy focusing on #particletherapy and #neoadjuvantchemotherapy in high-grade, locally advanced malignancies. #ESMOGuidelines 🔗ow.ly/5UwW50UUEvj

Systematic review on individualization of systemic therapies for locoregionally advanced NPC in ESMO Open. Extensive review of available clinical data, while waiting for results of studies exploring personalized approaches to (de)escalate treatments. esmoopen.com/article/S2059-…